Liraglutide for Weight Loss
The first GLP-1 medication approved for weight management, now complemented by newer options.
Medically reviewed by GlobalGLP1 Editorial Team • Updated April 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Liraglutide was a pioneering GLP-1 receptor agonist — the first in its class approved for chronic weight management (as Saxenda in 2014). While newer medications like semaglutide and tirzepatide have shown greater efficacy, liraglutide remains a viable option, particularly for patients who may not tolerate weekly injections or prefer a daily dosing schedule.
How Liraglutide Works
Like semaglutide, liraglutide activates GLP-1 receptors in the brain, pancreas, and gut. It reduces appetite, stimulates insulin release, and slows gastric emptying. The key difference from semaglutide is its shorter half-life (13 hours vs. 7 days), requiring daily rather than weekly injections.
FDA Approvals
Victoza
Type 2 diabetes mellitus
0.6 mg, 1.2 mg, 1.8 mg daily injection
Saxenda
Chronic weight management
0.6 mg to 3.0 mg daily injection (escalating dose)
Dosing & Administration
Daily injection schedule requires more commitment than weekly options. Some patients prefer the flexibility of choosing injection time. The pen is pre-filled and easy to use.
Weight Loss Efficacy
In the SCALE trial, participants on Saxenda lost an average of 8% of their body weight over 56 weeks, compared to 2.6% with placebo. About one-third of participants lost 10% or more. While less than newer GLP-1s, this remains clinically significant.
A1C Reduction: 0.8-1.1% A1C reduction (Victoza, for diabetes)
Side Effects
Common Side Effects
- Nausea (very common initially)
- Diarrhea
- Constipation
- Vomiting
- Low blood sugar (with diabetes medications)
- Decreased appetite
- Headache
- Dizziness
Serious (Rare)
- Pancreatitis
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning)
- Increased heart rate
- Kidney problems
- Suicidal thoughts (rare, monitored)
Managing side effects: Slow dose escalation over 5 weeks helps minimize nausea. Taking the injection at the same time each day and avoiding large meals can help. Report any persistent side effects to your provider.
Cost & Savings
Savings programs: Novo Nordisk offers Saxenda savings cards for eligible patients. The NovoCare program provides assistance for uninsured patients.
Who Should Not Take Liraglutide
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Known hypersensitivity to liraglutide
- Pregnancy
- History of pancreatitis
Cardiovascular Effects
The LEADER trial studied liraglutide 1.8 mg (Victoza dose) in over 9,300 patients with type 2 diabetes and high cardiovascular risk over 3.8 years. Liraglutide reduced the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 13%. Cardiovascular death alone was reduced by 22%.
What this means for you: Liraglutide was the first GLP-1 to demonstrate cardiovascular benefit, though at the lower diabetes dose (1.8 mg), not the weight-loss dose (3.0 mg). The cardiovascular benefit for the weight-loss indication has not been separately confirmed.
Timeline: What to Expect
Mild appetite suppression begins. Effects are more gradual compared to semaglutide due to lower receptor binding affinity.
Reaching maintenance dose (3.0 mg) over 5 weeks. Early weight loss of 1-2% body weight during escalation.
Consistent loss of 0.5-1 lb per week. GI side effects typically resolved by this point.
Average 5-8% body weight lost. Some patients achieve 10%+. Blood sugar and blood pressure improvements measurable.
Weight loss stabilizes. Continued use needed to maintain results. Some patients see gradual additional loss through year 2.
Drug Interactions
Increases hypoglycemia risk. Reduce insulin or sulfonylurea dose when adding liraglutide. More relevant than with weekly GLP-1s due to daily dosing.
Delays gastric emptying, potentially affecting oral drug absorption. Effects are less pronounced than with semaglutide due to shorter half-life.
Monitor INR when starting liraglutide. Dose adjustments may be needed during the escalation period.
Liraglutide delays acetaminophen absorption (Cmax reduced by 31% in studies). Clinical significance is minimal for most patients.
Special Populations
Contraindicated. Discontinue at least 2 weeks before planned conception (shorter washout than semaglutide due to shorter half-life).
Use caution in renal impairment. No dose adjustment, but dehydration from GI effects can worsen renal function. Limited experience in severe impairment.
Use caution in hepatic impairment. Limited experience. Not recommended in severe hepatic impairment.
No dose adjustment needed. Greater sensitivity possible. The LEADER trial included patients up to 80 years old.
Saxenda is FDA-approved for adolescents aged 12+ with body weight above 60 kg and obesity. Dosing follows the same escalation as adults.
After Stopping Treatment
Studies show weight regain is common after stopping Saxenda, similar to other GLP-1 medications. The SCALE maintenance study showed patients who continued liraglutide maintained 6% body weight loss versus 0% in those switched to placebo over 56 weeks.
Mitigation strategies: Building sustainable habits during treatment is essential. Consider transitioning to a weekly GLP-1 if long-term therapy is planned, as weekly dosing improves adherence. Behavioral counseling and exercise programs should continue after stopping.
Frequently Asked Questions
Saxenda can still be appropriate for certain patients: those who prefer daily dosing, can't tolerate semaglutide or tirzepatide, or whose insurance covers Saxenda but not newer medications. Discuss all options with your healthcare provider.
Liraglutide (Saxenda) has a half-life of about 13 hours, while semaglutide (Ozempic/Wegovy) has a half-life of about 7 days. The longer half-life of semaglutide allows for once-weekly dosing.
Yes, switching from liraglutide to semaglutide is common and generally straightforward. Your doctor will typically stop Saxenda and start the semaglutide escalation schedule. No washout period is needed.
Clinical data shows semaglutide (Ozempic/Wegovy) produces significantly more weight loss than liraglutide (Saxenda). The STEP 8 trial directly compared the two and found semaglutide produced about twice the weight loss.
Compare Liraglutide providers by pricing, telehealth availability, and patient ratings.
Search Liraglutide Clinics →Find Liraglutide Clinics by State
Ready to start Liraglutide?
Search our directory of 2,770 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.